Detail akcie Schrodinger Rg online

Business Summary: Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Schrodinger Inc revenues increased 41% to $168.6M. Net loss decreased 8% to $135.8M. Revenues reflect Software segment increase of 29% to $130.2M, Drug discovery segment increase from $18.5M to $38.4M, EMEA segment increase from $12.3M to $52.4M, United States segment increase of 21% to $95M. Lower net loss reflects Research and development - Balancing val decrease of 13% to $121.6M (expense).